title: Cost-effectiveness of PCSK9 Inhibitor Therapy-Reply.
authors.affiliation: Department of Medicine, University of California, San Francisco.
authors.forename: Dhruv S
authors.initials: DS
authors.lastname: Kazi
authors.affiliation: College of Physicians and Surgeons, Columbia University, New York, New York.
authors.forename: Andrew E
authors.initials: AE
authors.lastname: Moran
authors.affiliation: Department of Medicine, University of California, San Francisco.
authors.forename: Kirsten
authors.initials: K
authors.lastname: Bibbins-Domingo
mesh_terms: D003362:Cost-Benefit Analysis; D006801:Humans; D043484:Proprotein Convertases; D012697:Serine Endopeptidases
chemical_list: D043484:Proprotein Convertases; D012697:Serine Endopeptidases